Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754206 | 0.86 | CES2 (0.39) | EPHX2ALDH1A1GAACES2THRB | |
| SCHEMBL25754203 | 0.79 | CES2 (0.47) | ALDH1A1TSHRCES2THRBZDHHC20 | |
| SCHEMBL25754341 | 0.77 | KDM4E (0.42) | ALDH1A1TSHRGAATHRBSMN1; SMN2 | |
| SCHEMBL25754328 | 0.76 | ZDHHC20 (0.32) | ALDH1A1TSHRZDHHC20 | |
| SCHEMBL9506337 | 0.75 | ALDH1A1 (0.54) | ALDH1A1TSHR | |
| SCHEMBL2123030 | 0.74 | CES2 (0.50) | ALDH1A1TSHRCES2 | |
| SCHEMBL25754223 | 0.74 | CES2 (0.55) | EPHX2ALDH1A1TSHRCES2THRB | |
| SCHEMBL25996476 | 0.72 | ALDH1A1 (0.44) | EPHX2ALDH1A1TSHRCES2THRB | |
| SCHEMBL25754218 | 0.71 | CES2 (0.47) | EPHX2ALDH1A1TSHRCES2THRB | |
| SCHEMBL9007940 | 0.71 | ALDH1A1 (0.54) | EPHX2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | EPHX2 2419/4885ALDH1A1 2539/4885TSHR 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.